As central banks in major economies hold interest rates steady amid geopolitical uncertainties, the Asian markets are navigating a complex landscape of currency fluctuations and evolving policy expectations. In this environment, identifying stocks that may be priced below their estimated value requires careful consideration of factors such as earnings resilience and sector-specific growth potential.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) |
HK$456.80 |
HK$892.96 |
48.8% |
|
SHIFT (TSE:3697) |
Â¥649.40 |
Â¥1274.37 |
49% |
|
Shanghai Putailai New Energy Technology GroupLtd (SHSE:603659) |
CNÂ¥36.27 |
CNÂ¥71.18 |
49% |
|
Premium Group (TSE:7199) |
Â¥1864.00 |
Â¥3665.16 |
49.1% |
|
KINX (KOSDAQ:A093320) |
â‚©106700.00 |
â‚©212459.46 |
49.8% |
|
JAC Recruitment (TSE:2124) |
Â¥851.00 |
Â¥1688.22 |
49.6% |
|
Inner Mongolia Xingye Silver & Tin Mining (SZSE:000426) |
CNÂ¥42.38 |
CNÂ¥84.50 |
49.8% |
|
HD-Hyundai Marine Engine (KOSE:A071970) |
â‚©107100.00 |
â‚©208484.21 |
48.6% |
|
Elan (TSE:6099) |
Â¥760.00 |
Â¥1478.86 |
48.6% |
|
ALT (KOSDAQ:A459550) |
â‚©2900.00 |
â‚©5744.65 |
49.5% |
Let’s uncover some gems from our specialized screener.
Overview: Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical technology sector, focusing on the development and commercialization of surgical robots, with a market cap of approximately HK$32.65 billion.
Operations: The company generates revenue primarily from the sale of medical devices, amounting to CNÂ¥551.07 million.
Estimated Discount To Fair Value: 16.1%
Shanghai MicroPort MedBot (Group) is trading at HK$31.66, below its estimated future cash flow value of HK$37.74, suggesting it may be undervalued based on cash flows. The company’s revenue is forecast to grow significantly at 30.4% per year, outpacing the Hong Kong market’s growth rate of 8.5%. Recent financials show a reduction in net loss from CNY 642.41 million to CNY 249.66 million in 2025, alongside robust global expansion and adoption of its Toumai Laparoscopic Surgical Robot system.
Overview: Singapore Technologies Engineering Ltd is a global technology, defence, and engineering company with a market cap of SGD33.68 billion.
Operations: The company’s revenue is derived from three main segments: Commercial Aerospace at SGD5.04 billion, Urban Solutions & Satcom at SGD2.08 billion, and Defence & Public Security at SGD5.39 billion.
Estimated Discount To Fair Value: 10.8%
Singapore Technologies Engineering is trading at S$10.79, slightly below its estimated future cash flow value of S$12.1, highlighting potential undervaluation based on cash flows. Despite a high debt level and reduced profit margins (3.7% from 6.2%), earnings are forecast to grow significantly at 21.73% annually over the next three years, outpacing Singapore’s market growth rate of 5.7%. Recent contract wins totaling $4.8 billion across various segments bolster its revenue prospects and global footprint expansion efforts.
Overview: Shenzhen Megmeet Electrical Co., LTD operates as an electrical automation company in China with a market cap of CNÂ¥69.53 billion.
Operations: Shenzhen Megmeet Electrical Co., LTD’s revenue segments include industrial automation, smart home appliances, and power supply products.
Estimated Discount To Fair Value: 10.6%
Shenzhen Megmeet Electrical is trading at CNÂ¥120.21, about 10.6% below its estimated future cash flow value of CNÂ¥134.52, suggesting undervaluation based on cash flows. The company reported Q1 revenue growth to CNY 2,787.76 million from CNY 2,316.34 million a year ago but experienced a decline in profit margins to 1.6% from last year’s 4.7%. Despite recent share price volatility and lower-than-expected return on equity forecasts, earnings are projected to grow significantly at 67% annually over the next three years.
Taking Advantage
Seeking Other Investments?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2252 SGX:S63 and SZSE:002851.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

















